Cronos Group (CRON.TO) Akcie Kurz
Cronos Group Kurz
Tržby rostly o 50,8 % ročně za posledních 10 let na 149,15 Mil. USD. Zisk na akcii rostl o 36,5 % ročně za posledních 9 let. čistá marže společnosti Cronos Group je nyní -6,4 %, nahoru z -613,5 % před několika lety. Medián cílové ceny analytiků je 3,34 USD, tedy pod aktuální cenu o 6,4 %. Z 8 analytiků jich 7 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Cronos Group
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Cronos Group a analýza akcií
Nejčastější otázky týkající se akcie Cronos Group
The business model of Cronos Group Inc. revolves around the cultivation, production, and distribution of cannabis and cannabis-derived products worldwide. As a leader in the cannabis industry, Cronos Group focuses on developing and building iconic brands, partnering with retail networks, and expanding distribution channels. By prioritizing innovation and research, Cronos Group aims to provide high-quality and differentiated cannabis products to its diverse customer base. With a strategic global presence and a commitment to sustainability, Cronos Group Inc. strives to drive industry growth and shape the future of cannabis.
Cronos Group Inc is primarily active in the cannabis industry.
The main competitors of Cronos Group Inc in the market are Canopy Growth Corporation, Aurora Cannabis Inc, and Tilray Inc.
Cronos Group Inc, a leading Canadian cannabis company, has a rich history and background. Founded in 2013, it quickly established itself as a pioneer in the cannabis industry. The company operates globally and focuses on developing and distributing high-quality cannabis products. Cronos Group Inc has successfully formed partnerships with renowned brands, such as Marlboro-maker Altria Group, enhancing its market position. With a commitment to innovation and sustainability, Cronos prides itself on its diverse portfolio of brands and a strong research and development team. As a market leader, Cronos Group Inc continues to shape the future of the cannabis industry with its dedication to excellence and commitment to delivering shareholder value.
Cronos Group Inc has achieved several significant milestones. The company became the first cannabis producer to be listed on a major stock exchange in 2018, trading on the NASDAQ under the ticker symbol CRON. Additionally, Cronos Group Inc expanded its global presence by entering strategic partnerships and acquisitions in various countries. These include a joint venture in Israel, a supply and distribution agreement in Germany, and a partnership in Australia. Furthermore, the company has focused on research and development initiatives to innovate and develop novel cannabinoid-based products. Cronos Group Inc continues to make strides in the cannabis industry, positioning itself for further growth and success.
Cronos Group Inc is primarily present in Canada and the United States.
Cronos Group Inc represents core values of integrity, innovation, and responsibility. As a leading global cannabinoid company, Cronos Group is committed to providing innovative and high-quality products to its customers. The company's corporate philosophy revolves around transparency, sustainability, and community partnerships. Cronos Group focuses on advancing cannabinoid research, developing industry-leading intellectual property, and driving the growth of the cannabis industry. With a commitment to regulatory compliance and ethical practices, Cronos Group Inc prioritizes the well-being and satisfaction of their stakeholders while promoting the benefits of cannabinoid-based therapies.
Analytici aktuálně stanovují průměrnou cílovou cenu 3,34 USD pro akcii Cronos Group (medián: 3,34 USD), tedy -3,1 % vůči poslední ceně. Konsensus vychází z 8 hodnocení analytiků.
9 analytiků aktuálně hodnotí akcii Cronos Group: 8 doporučuje koupit, 1 držet a 0 prodat. Pro rok 2026 analytici očekávají u Cronos Group tržby 209,07 Mil. USD a zisk na akcii 0,16 USD.
Při aktuálním kurzu se akcie Cronos Group obchoduje za 3,19 EUR (3,57 USD).
Akcie Cronos Group (CRON.TO) je kótována na 5 burzách, mimo jiné: NASDAQ (CRON), Toronto (CRON.TO), Frankfurt (7CI.F), München (7CI.MU), Düsseldorf (7CI.DU).
The Cronos Group Inc is a Canadian company that operates in the manufacturing and marketing of cannabis products. Cronos' business model is based on vertical integration, allowing the company to complete all steps from cultivation to sales under one roof. One of Cronos' core divisions is cannabis cultivation. The company operates its own cultivation areas in Canada and other countries, equipped with the latest technology and highest standards. Through outdoor and indoor cultivation, Cronos can offer a wide range of cannabis varieties that cater to individual customer needs. Another important aspect of Cronos is the production of cannabis extracts and derivatives. The company utilizes its own cultivation areas and processes the harvested material into high-quality products such as oils, tinctures, capsules, and vapes. The broad portfolio of cannabis derivatives allows Cronos to target different market segments and cover a wide range of applications. In addition to production, Cronos also offers comprehensive consulting services. Experienced consultants and experts are available to assist customers in selecting the right product and individual dosage. This builds trust and customer satisfaction and strengthens the company's image as a responsible cannabis provider. Cronos markets its products through various channels, including its own online shop, retailers, and wholesalers. The company has been particularly successful in international marketing. Cronos collaborates with partners in different countries to position its products in the global market. The company focuses on a high-quality brand strategy and clear positioning as a premium provider. In addition to the mentioned business areas, Cronos also invests in research and development. This is aimed at strengthening the company's position as an innovation leader in the cannabis industry and exploring new applications. One focus is on the medical use of cannabis derivatives, which have shown positive effects in numerous medical conditions. Overall, Cronos' business model is characterized by a clear strategy, professional management, and a broad portfolio of high-quality products. Successful international marketing and positioning as a premium provider contribute significantly to the company's success. Investments in research and development will continue to support Cronos in offering innovative products and expanding its market position.
Tržby očekávané za Cronos Group činí 209,07 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Cronos Group činí 63,09 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Cronos Group je aktuálně 21,65. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Cronos Group.
Poměr ceny k tržbám (P/S) Cronos Group je aktuálně 6,53. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Cronos Group.
Score kvality pro Cronos Group je 3/10.
ISIN Cronos Group je CA22717L1013. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Cronos Group je A2DMQY. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Cronos Group je CRON.TO. Symbol tickeru se používá k obchodování akcií Cronos Group na burze.
Cronos Group akcie
Cronos Group Peer Group
Cronos Group Ticker
Cronos Group FIGI
Všechny fundamentální údaje o Cronos Group v podrobné analýze
Naše analýzy akcií společnosti Cronos Group zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Cronos Group. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: